Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
NCT01694381 · TSI, LLC · EARLY_PHASE1 · terminated · last registry update 2021-01-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, TSI, LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against VDR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-11-18Phase 3 first posted: Ultragenyx Pharmaceutical Inc, Setrusumab (NCT05125809)
- 2021-08-24Phase 3 first posted: Diamyd Medical AB, Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel® + Placebo (NCT05018585)
- 2021-08-17Phase 3 first posted: VA Office of Research and Development, Vitamin D (NCT05008484)
- 2021-07-26Results posted on the registry: University of North Carolina, Chapel Hill, Omega-3 fatty acids (fish oil) + Vitamin D3 (cholecalciferol) (NCT03313076)
- 2021-05-04Phase 3 first posted: Ottawa Hospital Research Institute, a drug against VDR (NCT04871412)
- 2021-03-29Results posted on the registry: Brigham and Women's Hospital, a drug against VDR (NCT01747447)
- 2021-01-08Results posted on the registry: Brigham and Women's Hospital, Fish Oil (NCT01351805)
- 2020-09-02Phase 3 first posted: Brigham and Women's Hospital, a drug against VDR (NCT04536298)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision